167 related articles for article (PubMed ID: 38646426)
1. Targeting estrogen mediated CYP4F2/CYP4F11-20-HETE metabolic disorder decelerates tumorigenesis in ER+ breast cancer.
Yang J; Li Y; Han X; Li T; Li D; Liu Q; Yan L; Li F; Pei X; Feng Y; Lin Z; Fu Z; Wang C; Sun Q; Li C
Biochem Biophys Rep; 2024 Jul; 38():101706. PubMed ID: 38646426
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of a common CYP4F11 genetic variant and identification of functionally defective CYP4F11 variants in erythromycin metabolism and 20-HETE synthesis.
Yi M; Cho SA; Min J; Kim DH; Shin JG; Lee SJ
Arch Biochem Biophys; 2017 Apr; 620():43-51. PubMed ID: 28347661
[TBL] [Abstract][Full Text] [Related]
3. ERα promotes
Wang Q; Zhang N; Yang X; Feng S; Wang F; Zhang W; He Z
Gland Surg; 2023 Jul; 12(7):963-973. PubMed ID: 37727335
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the Role of Fatty Acid-Metabolizing CYP4F11 in Lung Cancer and Its Potential As a Drug Target.
Jia H; Brixius B; Bocianoski C; Ray S; Koes DR; Brixius-Anderko S
Drug Metab Dispos; 2024 Jan; 52(2):69-79. PubMed ID: 37973374
[TBL] [Abstract][Full Text] [Related]
5. Effect of Genetic Variability in the
Zhang JE; Klein K; Jorgensen AL; Francis B; Alfirevic A; Bourgeois S; Deloukas P; Zanger UM; Pirmohamed M
Front Pharmacol; 2017; 8():323. PubMed ID: 28620303
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11.
Edson KZ; Prasad B; Unadkat JD; Suhara Y; Okano T; Guengerich FP; Rettie AE
Biochemistry; 2013 Nov; 52(46):8276-85. PubMed ID: 24138531
[TBL] [Abstract][Full Text] [Related]
8. Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer.
Jiang CF; Shi ZM; Li DM; Qian YC; Ren Y; Bai XM; Xie YX; Wang L; Ge X; Liu WT; Zhen LL; Liu LZ; Jiang BH
Mol Cancer; 2018 Apr; 17(1):83. PubMed ID: 29685157
[TBL] [Abstract][Full Text] [Related]
9. Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation.
Sun Y; Wang Y; Fan C; Gao P; Wang X; Wei G; Wei J
Mol Cancer; 2014 Jun; 13():137. PubMed ID: 24889938
[TBL] [Abstract][Full Text] [Related]
10. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-induced hypomethylation and overexpression of YAP1 facilitate breast cancer cell growth and survival.
Muhammad JS; Guimei M; Jayakumar MN; Shafarin J; Janeeh AS; AbuJabal R; Eladl MA; Ranade AV; Ali A; Hamad M
Neoplasia; 2021 Jan; 23(1):68-79. PubMed ID: 33242831
[TBL] [Abstract][Full Text] [Related]
13. Low GPR81 in ER
Yu J; Du Y; Liu C; Xie Y; Yuan M; Shan M; Li N; Liu C; Wang Y; Qin J
Life Sci; 2024 May; 350():122763. PubMed ID: 38823505
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer.
Abderrahman B; Maximov PY; Curpan RF; Hanspal JS; Fan P; Xiong R; Tonetti DA; Thatcher GRJ; Jordan VC
Mol Pharmacol; 2020 Oct; 98(4):364-381. PubMed ID: 32788222
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 Family
Alade AN; Claw KG; McDonald MG; Prasad B; Rettie AE; Thummel KE
ACS Pharmacol Transl Sci; 2024 Mar; 7(3):716-732. PubMed ID: 38481683
[TBL] [Abstract][Full Text] [Related]
16. Estrogen regulates miRNA expression: implication of estrogen receptor and miR-124/AKT2 in tumor growth and angiogenesis.
Jiang CF; Li DM; Shi ZM; Wang L; Liu MM; Ge X; Liu X; Qian YC; Wen YY; Zhen LL; Lin J; Liu LZ; Jiang BH
Oncotarget; 2016 Jun; 7(24):36940-36955. PubMed ID: 27175587
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
18. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
Zou Y; Tsai WB; Cheng CJ; Hsu C; Chung YM; Li PC; Lin SH; Hu MC
Breast Cancer Res; 2008; 10(1):R21. PubMed ID: 18312651
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor α regulates the expression of syndecan-1 in human breast carcinoma cells.
Fleurot E; Goudin C; Hanoux V; Bonnamy PJ; Levallet J
Endocr Relat Cancer; 2019 Jun; 26(6):615-628. PubMed ID: 30978702
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
